Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 17/20 | 0.44 |
| ▸ | ITGB6 | P18564 | 3/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 15/20 | 0.41 |
| ▸ | ITGB5 | P18084 | 9/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7005713 | 0.93 | ITGAV (0.41) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| SCHEMBL30335954 | 0.92 | ITGAV (0.47) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| SCHEMBL7007445 | 0.92 | ITGAV (0.47) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| Hydrochloric Acid SCHEMBL20481212 | 0.90 | ITGAV (0.47) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| SCHEMBL20139919 | 0.90 | ITGAV (0.46) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| SCHEMBL17640902 | 0.87 | ITGAV (0.52) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| SCHEMBL19384679 | 0.87 | ITGAV (0.52) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| Hydrochloric Acid SCHEMBL20305074 | 0.86 | ITGAV (0.51) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| Hydrochloric Acid SCHEMBL20305071 | 0.86 | ITGAV (0.51) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| SCHEMBL21767649 | 0.83 | ITGAV (0.53) | ITGAVITGB6ITGB3ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020047239-A1 | INHIBITING αV β6 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| US-6358970-B1 | FOR THERAPY AND PROPHYLAXIS OF OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, ARTHRITIS, VIRAL DISEASE, CANCER, AND METASTATIC TUMOR GROWTH | MERCK & CO., INC. | 2002-03-19 | — | — | US | disclosed |